Recursion Pharmaceuticals Financial Ratios
NASDAQ: RXRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Recursion Pharmaceuticals ratio analysis
Recursion Pharmaceuticals earned a net margin of -863.4% in FY 2025, down from -788.0% a year earlier. Gross margin was 5.0% compared with a median of 23.1% over the prior 5 years. Return on equity reached -57.0%, meaning Recursion Pharmaceuticals generated -0.57 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.02 versus 0.03 the year before, and the current ratio was 5.50. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Recursion Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Price / sales | 25.16 | 36.35 | 45.98 | 33.97 | 210.97 | — | — |
| Price / book | 1.66 | 2.07 | 4.42 | 2.79 | 3.95 | — | — |
| Gross margin | 5.0% | 23.1% | 4.5% | -21.2% | 100.0% | 100.0% | — |
| Operating margin | -867.9% | -814.1% | -785.3% | -616.7% | -1,795.8% | -2,135.7% | -2,692.6% |
| Net margin | -863.4% | -788.0% | -736.0% | -601.0% | -1,832.2% | -2,196.0% | -2,668.3% |
| Free cash flow margin | -506.5% | -633.7% | -672.4% | -302.6% | -1,949.4% | -1,293.0% | -2,628.4% |
| Return on equity (ROE) | -57.0% | -44.8% | -70.8% | -49.3% | -34.3% | — | — |
| Return on assets (ROA) | -43.7% | -32.0% | -50.2% | -34.1% | -30.6% | -29.1% | — |
| Debt / equity | 0.02 | 0.03 | 0.00 | 0.00 | 0.00 | — | — |
| Current ratio | 5.50 | 3.81 | 4.70 | 5.68 | 11.46 | 11.53 | — |
| Revenue growth | 26.9% | 32.0% | 11.9% | 291.5% | 156.9% | 70.8% | — |